| JNJ 24831754ZAE |
| (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol |
| (CAS 842133-18-0) |
 |
| Description： |
Canagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes.[1][2] It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.[3]
|
| Product No. |
KT00240 |
| Product Name |
JNJ 24831754ZAE |
| Synonyms |
Canagliflozin |
| Formal Name |
(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol |
| CAS Number |
842133-18-0 |
| Molecular Formula |
C24H25FO5S |
| Formula Weight |
444.52 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Canagliflozin hemihydrate
Dapagliflozin
Dapagliflozin (2S)-1,2-propanediol, hydrate
Empagliflozin
Ipragliflozin
LX-4211
PF-04971729
|
|
